Provider: Thomson Reuters Stock Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Benitec Biopharma Ltd announces positive lung cancer preclinical results
Benitec Biopharma Ltd:Says the results of pre-clinical experiments confirming the ability to significantly increase survival in non-small cell lung cancer (NSCLC) in vivo.Says Tribetarna (a ddRNAi‐based therapeutic) provides significantly increased survival in a preclinical in vivo model of lung cancer.Says After six weeks 78 pct. of animals dosed with a combination of Tribetarna and cisplatin lived, compared with only 20 pct. of the animals in the control groups.Says the study confirms previously reported results that silencing the gene target of Tribetarna, beta III tubulin, overcomes the resistance of NSCLC tumours to chemotherapy.Says preliminary submission filed with the US FDA.
Latest Developments for Benitec Biopharma Ltd
Latest Key Developments in Biotechnology
- Immunomedics announces Orphan Drug designation for Veltuzumab for treatment of Pemphigus
- Neptune Technologies & Bioressources Inc appoints President & CEO
- Proteo Inc and Proteo Biotech AG announces final analysis of phase II clinical study on Elafin in Coronary Artery Bypass Surgery Completed
- Novogen Limited announces identification of lead ATM drug candidate
- Share this
- Digg this